Loading…
Loading the latest PSX data…
Loading the latest PSX data…
Citi Pharma Ltd. (CPHL), GlaxoSmithKline Pakistan Limited (GLAXO), Abbott Laboratories (Pakistan) Limited (ABOT): performance, valuation, growth, risk and danioPSX score, side by side.
Add a stock
Growth of Rs 100 from 2025-11-10
Daily closes from PSX end-of-day files, adjusted for bonus shares, right issues and splits (not for cash dividends). KSE-100: official closes where available, otherwise rebuilt from its constituents.
| Measure | CPHLPharmaceuticals | GLAXOPharmaceuticals | ABOTPharmaceuticals |
|---|---|---|---|
| danioPSX score | 33 | 90 | 83 |
| Price and size | |||
| Price | Rs 63.42 | Rs 336.36 | Rs 1,000.00 |
| Today | −0.21% | −0.57% | +0.52% |
| Market cap | Rs 14.5bn | Rs 107.1bn | Rs 97.9bn |
| Traded per day | Rs 49m | Rs 49m | Rs 14m |
| Valuation and dividends | |||
| P/E | 17.8 | 9.8 | 10.5 |
| Dividend yield | – | 6.1% | 4.4% |
| EPS (last year) | Rs 3.43 | Rs 31.48 | Rs 81.37 |
| Business | |||
| EPS growth | −12.1% | +53.4% | +52.2% |
| Sales growth | +6.5% | +7.7% | +10.6% |
| Net margin | 5.6% | 15.2% | 10.6% |
| Returns | |||
| 1 month | −0.1% | +7.7% | +7.4% |
| 3 months | −13.0% | −2.4% | +8.2% |
| 1 year | −22.6% | −14.9% | −6.9% |
| vs KSE-100, 1 year | -35.7 pts | -28.0 pts | -20.0 pts |
| Trend and risk | |||
| 52-week position | 19% | 26% | 40% |
| RSI 14 | 50 | 62 | 65 |
| RS rank | 14 | 38 | 65 |
| Volatility | 38% | 34% | 30% |
| Beta | 1.10 | 1.05 | 0.77 |
| danioPSX score | |||
| Value | 37 | 73 | 67 |
| Quality | 56 | 81 | 74 |
| Dividend | 0 | 64 | 35 |
| Momentum | 14 | 40 | 62 |
| Safety | 74 | 79 | 76 |
| Shariah-compliant | Yes | Yes | Yes |
Bold marks the best value in each row where higher (or, for P/E and volatility, lower) is clearly better.
A comparison of published numbers, not a recommendation. Share this page: the address holds the stocks. Find more stocks with the screener